zinc finger protein 717Genealiases: OB1 · X17 · ZNF838
Q-omics provides the consensus-scored ZNF717 profile across patient tissues and cancer cell-line models. ZNF717 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ZNF717 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF717 RNA expression shows 20,165 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, THCA, and ACC as cancer lineages where ZNF717 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF717 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF717 survival associations across molecular data types. ZNF717 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF717 RNA expression–survival associations across cancer types. High ZNF717 expression shows unfavorable associations in ACC and CESC, but favorable associations in READ, UCS, UVM and OV. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for ZNF717 RNA expression.
This table summarizes ZNF717 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF717. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF717 shows lower tumor expression in THCA, KIRC, KICH, UCEC and HNSC and higher tumor expression in COAD. The THCA box plot shows higher ZNF717 RNA expression in normal versus tumor tissue (log2 FC = −0.590, t-test p < 0.001).
This table shows molecular features associated with ZNF717 in patient tissues and cancer cell lines. In patient samples, ZNF717 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF717 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
